License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, $ in Thousands, £ in Millions			1 Months Ended					3 Months Ended			12 Months Ended
	Sep. 21, 2022 USD ($) $ / shares shares	Jan. 15, 2021 USD ($)	Nov. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 GBP (£)	May 31, 2016 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Nov. 07, 2022 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total milestone								$ 95,000			$ 95,000
Deferred Revenue, Current								2,132			2,132	$ 4,149
Revenue recognized											933	2,503
Common stock issued, aggregate fair value											221	14,234
Remaining Transaction Price Allocated To Performance Obligations								12,500			12,500
Milestone payment								225,000			225,000
GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial Payments Amount to Perform the Obligations												66,000
Discount on Performance of Obligations												1,300
Total milestone								30,000			30,000
Issuance of common stock, net of issuance costs, shares | shares	7,450,000
Common stock issued, aggregate fair value	$ 10,300
Remaining Transaction Price Allocated To Performance Obligations								64,700			64,700
Milestone payment								21,200			21,200
License and Know-How Transfer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price											1,400
License and Know-How Transfer [Member] | GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Remaining Transaction Price Allocated To Performance Obligations												64,700
Performance Obligation Allocated Transaction Price												45,700
Research And Development Services Related To Upcoming Milestones [Member] | GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized												19,000
Cantab Related Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment upon achievement of specified commercial milestone						£ 5.0					6,400
License agreement research and development expense related to achievement of regulatory milestones											$ 0	0
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones					$ 5,800
Vertex License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract termination period											10 years
Nonrefundable upfront payments							$ 500
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones							$ 80,200
License agreement payment of research and development expense related to achievement of regulatory milestones											$ 0	0
Contract termination period if no material development or commercialization occurs											1 year
Meiji License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments				$ 600
Sublicense fee payable to counter party												7,500
Sublicence Fee Paid												6,600
Potential milestone payments upon achievement of specified condition				$ 1,000
License agreement fixed assets related payments										$ 1,600
Remaining Sublicence Fee Paid to Counter Party								900			$ 900
Potential milestone payments upon completion and delivery of results of a clinical study												1,000
Future milestone payments											1,000
Performance Obligation Allocated Transaction Price											95,800
Total Received Milestone								30,000			$ 30,000
Everest License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Period of option granted on an agreement											12 months
Revenue recognized											$ 0	700
Milestone payment								34,000			34,000
Everest License Agreement [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
milestones payment received		$ 2,000
Everest License Agreement [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		180 days
Everest License Agreement [Member] | Maximum [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone		$ 38,000						$ 59,500			59,500
Everest License Agreement [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		90 days
Pfizer License and Share Purchase Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone									$ 900
milestones payment received									5,000
Deferred Revenue, Current												13,000
Revenue recognized											$ 900	1,800
Issuance of common stock, net of issuance costs, shares | shares											2,362,348
Common stock issued, aggregate fair value											$ 27,500
Associated premium as a freestanding equity-linked instrument under ASC 815											12,500
Performance Obligation Allocated Transaction Price									5,000
Pfizer License and Share Purchase Agreements [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received											$ 0
Issuance of common stock, net of issuance costs, shares | shares											2,362,348
Share price | $ / shares								$ 16.93			$ 16.93
Proceeds from sale of common stock to related party											$ 40,000
Receivable amount upon achievement of certain milestone											80,000
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price									$ 4,100		11,100
Gates MRI [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
buy back certain materials								$ 700
Savior Service Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses								5,300			5,300
Savior Service Agreement [Member] | Prepaid Expenses and Other Current Assets [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable supervision fee related to commercial manufacturing facility			$ 2,000
Savior Service Agreement [Member] | Long-term Asset [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service agreement additional payment related to facility build out costs			$ 5,300
GSK License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Revenue, Current								48,600			48,600
Issuance of common stock, net of issuance costs, shares | shares	7,450,000
Share price | $ / shares	$ 1.20805
Common stock issued, aggregate fair value	$ 1,300
Performance Obligation Allocated Transaction Price												46,100
GSK License Agreement [Member] | Glaxo Smith Kline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment								23,800			23,800			$ 4,300	$ 66,000
Change in subsequent payments															50.00%
GSK License Agreement [Member] | GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total milestone								95,000			95,000
Milestone Achievement Research And Development Services								64,700			64,700
Milestone payment								23,800			23,800
Total Received Milestone								95,000			95,000		$ 30,000
Significant financing component											2,500
Milestone Allocated Research And Development Services								$ 8,800			8,800
GSK License Agreement [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized												45,700
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price												$ 400
Total potential additional milestones											$ 3,200